Share on StockTwits

Salix Pharmaceuticals (NASDAQ:SLXP) CEO Carolyn J. Logan sold 53,057 shares of the company’s stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $123.38, for a total value of $6,546,172.66. Following the completion of the sale, the chief executive officer now directly owns 621,407 shares in the company, valued at approximately $76,669,196. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Salix Pharmaceuticals (NASDAQ:SLXP) traded up 0.44% on Monday, hitting $123.35. The stock had a trading volume of 749,214 shares. Salix Pharmaceuticals has a one year low of $64.93 and a one year high of $126.60. The stock has a 50-day moving average of $113.6 and a 200-day moving average of $104.2. The company has a market cap of $7.821 billion and a price-to-earnings ratio of 104.34.

Salix Pharmaceuticals (NASDAQ:SLXP) last issued its quarterly earnings data on Thursday, May 8th. The company reported $1.05 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.91 by $0.14. The company had revenue of $384.00 million for the quarter, compared to the consensus estimate of $372.91 million. During the same quarter last year, the company posted $0.63 earnings per share. Salix Pharmaceuticals’s revenue was up 89.7% compared to the same quarter last year. On average, analysts predict that Salix Pharmaceuticals will post $6.52 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on SLXP shares. Analysts at Canaccord Genuity initiated coverage on shares of Salix Pharmaceuticals in a research note on Friday. They set a “buy” rating and a $145.00 price target on the stock. Separately, analysts at Stifel Nicolaus raised their price target on shares of Salix Pharmaceuticals to $130.00 in a research note on Friday, June 13th. Finally, analysts at Stifel Nicolaus raised their price target on shares of Salix Pharmaceuticals from $120.00 to $130.00 in a research note on Friday, June 13th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $119.35.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.